David Davidson, MD
Cardiovascular Disease · Bannockburn, ILNPI 1063679116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $228,417 of the $265,183 with a category attached, or 86.1%. 30 manufacturers reported payments, led by Novo Nordisk at 46.9% of the total. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $722.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$124K
- Amgen$54K
- Esperion Therapeutics, Inc.$28K
- Amryt Pharma Holdings Ltd$17K
- Sanofi-aventis U.S. LLC$13K
- Regeneron Healthcare Solutions, Inc.$9K
- plus $20K from 24 others
Across 27 payments — averaging $7985.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$59K
- AstraZeneca$45K
- Novartis$43K
- Akcea Therapeutics, Inc.$33K
- Regeneron$18K
- Astrazeneca UK Limited$18K
What the payments were for
- Consulting fees$22,8059%
- Speaking & faculty fees$228,41786%
- Travel & lodging$4,9452%
- Food & beverage$8,9833%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 91 | $124,335 |
| Amgen | 89 | $53,745 |
| Esperion Therapeutics, Inc. | 23 | $28,431 |
| Amryt Pharma Holdings Ltd | 12 | $16,718 |
| Sanofi-aventis U.S. LLC | 15 | $13,319 |
| Regeneron Healthcare Solutions, Inc. | 17 | $8,896 |
| Ionis Pharmaceuticals, Inc. | 3 | $8,659 |
| Heartflow, Inc. | 8 | $6,750 |
| Akcea Therapeutics, Inc. | 1 | $1,820 |
| Boehringer Ingelheim | 20 | $468 |
| AstraZeneca | 14 | $293 |
| Novartis | 12 | $204 |
| Boston Scientific | 10 | $177 |
| Merck | 7 | $160 |
| Medtronic | 3 | $148 |
| E.r. Squibb & Sons, L.L.C. | 6 | $146 |
| Abiomed | 5 | $142 |
| Johnson & Johnson | 6 | $119 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $114 |
| Abbott | 5 | $107 |
| Pfizer | 3 | $95 |
| Bridgebio Pharma, Inc. | 4 | $95 |
| Lilly USA, LLC | 3 | $50 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $31 |
| Lantheus Medical Imaging, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$265,183 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 379 | $415,326 |
| OzempicSemaglutide | 119 | $163,930 |
| Praluent PenAlirocumab | 107 | $92,172 |
| EliquisApixaban | 54 | $70,128 |
| XareltoRivaroxaban | 24 | $38,390 |
| WegovySemaglutide | 16 | $21,280 |
| JardianceEmpagliflozin | 12 | $16,529 |
| Icosapent Ethyl | 30 | $14,931 |
| VascepaIcosapent Ethyl | 13 | $13,297 |
| NexletolBempedoic Acid | 12 | $13,131 |
| Ezetimibe | 543 | $13,095 |
| TrulicityDulaglutide | 13 | $12,199 |
| Rosuvastatin Calcium | 516 | $5,022 |
| Ranolazine ErRanolazine | 15 | $2,477 |
| Atorvastatin Calcium | 231 | $1,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $124,335 | $185,211135 claims |
| PfizerEliquis | $95 | $70,12854 claims |
| Johnson & JohnsonXarelto | $119 | $38,39024 claims |
| Boehringer IngelheimJardiance | $468 | $16,52912 claims |
| Esperion Therapeutics, Inc.Nexletol | $28,431 | $13,13112 claims |
| Lilly USA, LLCTrulicity | $50 | $12,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Bannockburn
- Jay AlexanderBannockburn$744K
- Ronald BergerBannockburn$150K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.